Karyopharm Short Term Debt vs Capital Stock Analysis

KPTI Stock  USD 0.73  0.04  5.19%   
Karyopharm Therapeutics financial indicator trend analysis is infinitely more than just investigating Karyopharm Therapeutics recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Karyopharm Therapeutics is a good investment. Please check the relationship between Karyopharm Therapeutics Short Term Debt and its Capital Stock accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Karyopharm Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
For more detail on how to invest in Karyopharm Stock please use our How to Invest in Karyopharm Therapeutics guide.

Short Term Debt vs Capital Stock

Short Term Debt vs Capital Stock Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Karyopharm Therapeutics Short Term Debt account and Capital Stock. At this time, the significance of the direction appears to have significant contrarian relationship.
The correlation between Karyopharm Therapeutics' Short Term Debt and Capital Stock is -0.24. Overlapping area represents the amount of variation of Short Term Debt that can explain the historical movement of Capital Stock in the same time period over historical financial statements of Karyopharm Therapeutics, assuming nothing else is changed. The correlation between historical values of Karyopharm Therapeutics' Short Term Debt and Capital Stock is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Short Term Debt of Karyopharm Therapeutics are associated (or correlated) with its Capital Stock. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Capital Stock has no effect on the direction of Short Term Debt i.e., Karyopharm Therapeutics' Short Term Debt and Capital Stock go up and down completely randomly.

Correlation Coefficient

-0.24
Relationship DirectionNegative 
Relationship StrengthInsignificant

Short Term Debt

Capital Stock

The total amount of a company's capital funded by shareholders through the issue and subscription of shares.
Most indicators from Karyopharm Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Karyopharm Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Karyopharm Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
For more detail on how to invest in Karyopharm Stock please use our How to Invest in Karyopharm Therapeutics guide.The Karyopharm Therapeutics' current Enterprise Value is estimated to increase to about 1.1 B, while Selling General Administrative is projected to decrease to under 67.5 M.
 2021 2022 2023 2024 (projected)
Gross Profit206.4M151.9M141.1M148.1M
Total Revenue209.8M157.1M146.0M153.3M

Karyopharm Therapeutics fundamental ratios Correlations

0.50.630.090.740.440.16-0.740.390.740.480.440.370.980.740.660.570.880.670.480.990.330.63-0.50.57-0.78
0.50.86-0.660.540.640.57-0.81-0.20.430.270.680.210.390.780.840.860.670.860.410.47-0.210.03-0.870.84-0.78
0.630.86-0.470.630.650.52-0.830.070.460.290.580.140.550.830.750.830.750.820.380.610.140.25-0.760.83-0.81
0.09-0.66-0.47-0.05-0.21-0.810.570.530.160.22-0.34-0.230.17-0.48-0.67-0.54-0.29-0.68-0.310.080.660.520.77-0.660.53
0.740.540.63-0.050.330.38-0.670.360.310.360.24-0.130.680.680.550.60.770.580.330.730.340.44-0.390.67-0.68
0.440.640.65-0.210.330.07-0.470.180.490.660.740.520.320.460.470.730.50.47-0.080.370.210.2-0.540.36-0.48
0.160.570.52-0.810.380.07-0.72-0.2-0.28-0.130.070.070.10.690.680.470.490.730.560.18-0.28-0.08-0.650.8-0.67
-0.74-0.81-0.830.57-0.67-0.47-0.72-0.09-0.41-0.27-0.46-0.36-0.67-0.97-0.94-0.77-0.92-0.97-0.66-0.740.09-0.220.88-0.940.99
0.39-0.20.070.530.360.18-0.2-0.090.170.33-0.33-0.050.40.25-0.18-0.080.22-0.10.110.360.780.630.250.03-0.07
0.740.430.460.160.310.49-0.28-0.410.170.310.60.410.750.380.460.510.50.430.130.740.130.31-0.390.27-0.45
0.480.270.290.220.360.66-0.13-0.270.330.310.510.440.360.250.210.310.430.18-0.020.360.330.47-0.250.07-0.34
0.440.680.58-0.340.240.740.07-0.46-0.330.60.510.580.340.320.640.740.480.57-0.070.4-0.22-0.02-0.680.31-0.53
0.370.210.14-0.23-0.130.520.07-0.36-0.050.410.440.580.310.250.50.340.410.430.110.33-0.240.03-0.520.11-0.43
0.980.390.550.170.680.320.1-0.670.40.750.360.340.310.680.590.460.810.60.50.990.360.66-0.390.5-0.7
0.740.780.83-0.480.680.460.69-0.970.250.380.250.320.250.680.840.70.870.90.720.730.080.36-0.780.94-0.93
0.660.840.75-0.670.550.470.68-0.94-0.180.460.210.640.50.590.840.820.840.990.550.66-0.320.04-0.950.86-0.95
0.570.860.83-0.540.60.730.47-0.77-0.080.510.310.740.340.460.70.820.690.820.080.55-0.07-0.04-0.810.77-0.78
0.880.670.75-0.290.770.50.49-0.920.220.50.430.480.410.810.870.840.690.860.580.870.070.37-0.750.79-0.95
0.670.860.82-0.680.580.470.73-0.97-0.10.430.180.570.430.60.90.990.820.860.590.67-0.240.09-0.940.92-0.97
0.480.410.38-0.310.33-0.080.56-0.660.110.13-0.02-0.070.110.50.720.550.080.580.590.5-0.10.41-0.460.62-0.61
0.990.470.610.080.730.370.18-0.740.360.740.360.40.330.990.730.660.550.870.670.50.30.59-0.480.58-0.77
0.33-0.210.140.660.340.21-0.280.090.780.130.33-0.22-0.240.360.08-0.32-0.070.07-0.24-0.10.30.770.44-0.130.1
0.630.030.250.520.440.2-0.08-0.220.630.310.47-0.020.030.660.360.04-0.040.370.090.410.590.770.140.09-0.23
-0.5-0.87-0.760.77-0.39-0.54-0.650.880.25-0.39-0.25-0.68-0.52-0.39-0.78-0.95-0.81-0.75-0.94-0.46-0.480.440.14-0.830.89
0.570.840.83-0.660.670.360.8-0.940.030.270.070.310.110.50.940.860.770.790.920.620.58-0.130.09-0.83-0.89
-0.78-0.78-0.810.53-0.68-0.48-0.670.99-0.07-0.45-0.34-0.53-0.43-0.7-0.93-0.95-0.78-0.95-0.97-0.61-0.770.1-0.230.89-0.89
Click cells to compare fundamentals

Karyopharm Therapeutics Account Relationship Matchups

Karyopharm Therapeutics fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets295.0M313.1M305.3M358.2M240.4M238.3M
Other Current Liab41.4M(6.4M)67.5M57.4M59.7M62.7M
Total Current Liabilities46.4M297K73.7M65.9M69.5M73.0M
Total Stockholder Equity49.8M50.5M(79.7M)(16.7M)(136.2M)(129.4M)
Property Plant And Equipment Net3.0M2.2M1.6M7.4M4.9M3.0M
Current Deferred Revenue2.3M297K69.1M25.1M28.8M15.7M
Net Debt(19.0M)32.0M(21.2M)37.8M124.8M131.0M
Retained Earnings(873.3M)(1.1B)(1.2B)(1.3B)(1.5B)(1.4B)
Accounts Payable985K4.5M1.6M2.8M3.1M3.5M
Cash128.9M85.9M190.5M135.2M52.2M101.6M
Non Current Assets Total21.3M23.5M47.2M31.4M6.5M6.2M
Non Currrent Assets Other16.2M(2.9M)44.9M23.4M1.6M1.6M
Other Assets714K34.3M45.6M633K1.00.95
Cash And Short Term Investments264.0M273.5M228.6M278.0M191.4M201.7M
Common Stock Shares Outstanding62.0M72.0M75.2M81.9M114.2M119.9M
Liabilities And Stockholders Equity295.0M313.1M305.3M358.2M240.4M238.3M
Non Current Liabilities Total245.2M262.2M385.0M374.8M307.2M322.5M
Other Current Assets1.5M559K20.4M20.9M12.5M13.1M
Other Stockholder Equity923.1M1.1B1.1B1.3B1.4B748.9M
Total Liab245.2M262.5M385.0M374.8M376.6M395.5M
Property Plant And Equipment Gross13.7M11.6M1.6M1.1M11.4M12.0M
Total Current Assets273.7M289.5M258.1M326.8M233.9M215.6M
Accumulated Other Comprehensive Income(37K)518K191K(638K)(161K)(169.1K)
Short Term Debt1.6M1.9M4.6M5.7M6.6M8.5M
Property Plant Equipment3.0M2.2M1.6M1.1M1.3M2.2M
Net Tangible Assets49.8M50.5M(79.7M)(16.7M)(15.0M)(14.2M)
Long Term Debt109.9M117.9M169.3M170.1M170.9M179.5M
Retained Earnings Total Equity(873.3M)(1.1B)(1.2B)(1.3B)(1.2B)(1.1B)
Short Term Investments133.1M163.3M38.2M142.8M139.2M115.6M
Capital Surpluse923.1M1.1B1.1B1.3B1.5B824.8M
Other Liab8.5M75.8M144.6M215.7M248.0M260.4M
Net Invested Capital159.6M168.5M169.3M170.1M34.7M33.0M
Net Working Capital232.2M216.3M201.9M284.3M164.4M233.5M
Short Long Term Debt Total111.5M119.8M169.3M173.0M177.0M162.5M

Currently Active Assets on Macroaxis

When determining whether Karyopharm Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Karyopharm Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Karyopharm Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Karyopharm Therapeutics Stock:
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Karyopharm Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
For more detail on how to invest in Karyopharm Stock please use our How to Invest in Karyopharm Therapeutics guide.
You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Karyopharm Therapeutics. If investors know Karyopharm will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Karyopharm Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.05)
Revenue Per Share
1.247
Quarterly Revenue Growth
0.077
Return On Assets
(0.34)
Return On Equity
(8.91)
The market value of Karyopharm Therapeutics is measured differently than its book value, which is the value of Karyopharm that is recorded on the company's balance sheet. Investors also form their own opinion of Karyopharm Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Karyopharm Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Karyopharm Therapeutics' market value can be influenced by many factors that don't directly affect Karyopharm Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Karyopharm Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Karyopharm Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Karyopharm Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.